| Nov 14 |
ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83
|
| Nov 14 |
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
|
| Nov 12 |
Life Sciences Investor Forum Agenda Announced for November 14th
|
| Nov 5 |
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
|
| Oct 22 |
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
|
| Oct 17 |
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
|
| Oct 15 |
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
|
| Oct 7 |
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 3 |
ZyVersa Therapeutics files for mixed shelf offering
|
